InsidersTradesSigma
Follow the 海正药业 share price and the full directors' dealings record of the company, a listed issuer based in China. Shares are quoted on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 海正药业 has logged 1 insider filings. Market capitalisation: €13.7bn. The latest transaction was disclosed on 2 August 2022 (Purchase). Among the most active insiders: 喻舜兵. The full history is accessible without an account.
1
Insider Decl.
n/a
Thresholds
€1,658
1 ops.
Buy Volume
n/a
n/a
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 7,765 of 29,063 companies
63.1
score / 100
Value70
Quality56
FCF yld12%
Earn yld4.0%
EV/EBITDA8.8x
ROE7.9%
Gross mgn45%
Net mgn5.1%
Debt/EBITDA1.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 August 2022
关于 海正药业
海正药业是一家中国制药公司，专注于药品的研发和制造。该公司在上海证券交易所上市。